DRW Securities’s BioNexus Gene Lab BGLC Stock Holding History

DRW Securities’s Portfolio BGLC Stock Details BGLC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-47,830	Closed	-$189K	–	1305
2025 Q4	$189K	Buy	47,830 +33,179	+226%	+$158K	0.01%	985
2025 Q3	$80.1K	Buy	+14,651	New	+$81.5K	﹤0.01%	1199

Other funds holding BGLC

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

DRW Securities's BGLC Position: Q1 2026 in Review

DRW Securities sold out of BioNexus Gene Lab (BGLC) in Q1 2026, closing a stake of 47,830 shares — an estimated $189K sold.

DRW Securities first reported a position in BGLC in Q3 2025 and held it in 2 quarters. The position peaked at $189K in Q4 2025. 2 funds tracked by Wall St. Rank hold BGLC as of Q1 2026.

DRW Securities reported no remaining BioNexus Gene Lab position as of Q1 2026 after selling out during the quarter.
DRW Securities sold 47,830 BioNexus Gene Lab shares in Q1 2026, an estimated $189K.
DRW Securities first reported a position in BioNexus Gene Lab in Q3 2025 and held it in 2 quarters.
DRW Securities's BioNexus Gene Lab position peaked at $189K in Q4 2025.
2 funds tracked by Wall St. Rank held BioNexus Gene Lab as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.